Reports of Biochemistry
and Molecular Biology
Thu, Nov 21, 2024
[Archive]
Volume 10, Issue 2 (Vol.10 No.2 Jul 2021)
rbmb.net 2021, 10(2): 204-215 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Roshandel E, Parkhideh S, Ghaffari Nazari H, Mehdizadeh M, Bonakchi H, Sankanian G et al . Pre-and Post-Transplant Serum Lactate Dehydrogenase Levels as a Predictive Marker for Patient Survival and Engraftment in Allogeneic Hematopoietic Stem Cell Transplant Recipients. rbmb.net 2021; 10 (2) :204-215
URL: http://rbmb.net/article-1-640-en.html
URL: http://rbmb.net/article-1-640-en.html
Elham Roshandel 
, Sayeh Parkhideh * , Haniyeh Ghaffari Nazari , Mahshid Mehdizadeh , Hossein Bonakchi , Ghazaleh Sankanian , Abbas Hajifathali
, Sayeh Parkhideh * , Haniyeh Ghaffari Nazari , Mahshid Mehdizadeh , Hossein Bonakchi , Ghazaleh Sankanian , Abbas Hajifathali
Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract: (3064 Views)
Background: The discovery of biomarkers to predict the development of complications associated with hematopoietic stem cell transplantation (HSCT) offers a potential avenue for the early identification and treatment of these life-threatening consequences. Serum lactate dehydrogenase (sLDH) has been identified as a potential biomarker for determining the outcome of allogenic HSCT (allo-HSCT).
Methods: A retrospective study was performed using data collected from 204 allo-HSCT recipient patients to examine the predictive value of sLDH levels pre- and post-allo-HSCT on patient survival, graft-versus-host-disease (GVHD) incidence, and time to platelet/white blood cells (WBC) engraftment.
Results: Our findings show that neither pre- (p= 0.61) nor post-transplantation (p= 0.55) sLDH levels were associated with GVHD incidence. However, elevated sLDH levels pre- and post-transplantation (≥ 386 and ≥ 409 IU/mL, respectively) were found to be adverse risk factors for patient survival (p= 0.16, p= 0.20, respectively). Furthermore, a median sLDH level≥ 400 IU/mL from day +5 to day +15 post-transplantation had a significant positive association with enhanced time to platelet and white blood cell (WBC) engraftment, compared to patients with sLDH levels < 400 IU/mL (p< 0.001).
Conclusions: Our data suggests that high sLDH levels pre- and post-allo-HSCT could be considered a predictor of poor patient survival. Furthermore, high levels of sLDH days 5-15 post-allo-HSCT could be associated with improved time to platelet and WBC engraftment; however, this appears to come at the cost of increased mortality risk.
Methods: A retrospective study was performed using data collected from 204 allo-HSCT recipient patients to examine the predictive value of sLDH levels pre- and post-allo-HSCT on patient survival, graft-versus-host-disease (GVHD) incidence, and time to platelet/white blood cells (WBC) engraftment.
Results: Our findings show that neither pre- (p= 0.61) nor post-transplantation (p= 0.55) sLDH levels were associated with GVHD incidence. However, elevated sLDH levels pre- and post-transplantation (≥ 386 and ≥ 409 IU/mL, respectively) were found to be adverse risk factors for patient survival (p= 0.16, p= 0.20, respectively). Furthermore, a median sLDH level≥ 400 IU/mL from day +5 to day +15 post-transplantation had a significant positive association with enhanced time to platelet and white blood cell (WBC) engraftment, compared to patients with sLDH levels < 400 IU/mL (p< 0.001).
Conclusions: Our data suggests that high sLDH levels pre- and post-allo-HSCT could be considered a predictor of poor patient survival. Furthermore, high levels of sLDH days 5-15 post-allo-HSCT could be associated with improved time to platelet and WBC engraftment; however, this appears to come at the cost of increased mortality risk.
Keywords: Engraftment, Graft versus host disease, Hematopoietic stem cell transplantation, Lactate dehydrogenase.
Type of Article: Original Article |
Subject:
Biochemistry
Received: 2021/01/14 | Accepted: 2021/02/8 | Published: 2021/08/26
Received: 2021/01/14 | Accepted: 2021/02/8 | Published: 2021/08/26
References
1. Gyurkocza B, Rezvani A, Storb RF. Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol. 2010;3(3):285-99. [DOI:10.1586/ehm.10.21] [PMID] [PMCID]
2. Bazinet A, Popradi G. A general practitioner's guide to hematopoietic stem-cell transplantation. Curr Oncol. 2019;26(3):187-191. [DOI:10.3747/co.26.5033] [PMID] [PMCID]
3. Paczesny S. Biomarkers for posttransplantation outcomes. Blood. 2018;17;131(20):2193-2204. [DOI:10.1182/blood-2018-02-791509] [PMID] [PMCID]
4. Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res. 2011;71(22):6921-5. [DOI:10.1158/0008-5472.CAN-11-1457] [PMID]
5. Wulaningsih W, Holmberg L, Garmo H, Malmstrom H, Lambe M, Hammar N, et al. Serum lactate dehydrogenase and survival following cancer diagnosis. Br J Cancer. 2015;113(9):1389-96. [DOI:10.1038/bjc.2015.361] [PMID] [PMCID]
6. Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol. 2015;54(7):961-70. [DOI:10.3109/0284186X.2015.1043026] [PMID]
7. Bolwell B, Pohlman B, Kalaycio M, Wise K, Goormastic M, Andresen S. LDH elevation after autologous stem cell transplantation. Bone Marrow Transplant. 1999;24(1):53-55. [DOI:10.1038/sj.bmt.1701812] [PMID]
8. Egan K, Singh V, Gidron A, Mehta J. Correlation between serum lactate ehydrogenase and stem cell mobilization. Bone Marrow Transplant. 2007;40(10):931-4. [DOI:10.1038/sj.bmt.1705851] [PMID]
9. Kalaycio M, Rybicki L, Pohlman B, Dean R, Sweetenham J, Andresen S, et al. Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia. Bone Marrow Transplant. 2007;40(8):753-8. [DOI:10.1038/sj.bmt.1705811] [PMID]
10. Mehta J, Gordon LI, Tallman MS, Winter JN, Evens AO, Frankfurt O, et al. Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?. Bone Marrow Transplant. 2006;38(2):95-100. [DOI:10.1038/sj.bmt.1705388] [PMID]
11. Song MK, Chung JS, Seol YM, Kwon BR, Shin HJ, Choi YJ, et al. Influence of lactate dehydrogenase and cyclosporine a level on the incidence of acute graft-versus-host disease after allogeneic stem cell transplantation. J Korean Med Sci. 2009;24(4):555-60. [DOI:10.3346/jkms.2009.24.4.555] [PMID] [PMCID]
12. Sung AD, Chao NJ. Concise review: acute graft‐versus‐host disease: immunobiology, prevention, and treatment. Stem Cells Transl Med. 2013;2(1):25-32. [DOI:10.5966/sctm.2012-0115] [PMID] [PMCID]
13. Ando T, Yamazaki E, Ogusa E, Ishii Y, Yamamoto W, Motohashi K, et al. Hashimoto C. Body mass index is a prognostic factor in adult patients with acute myeloid leukemia. Int J Hematol. 2017;105(5):623-630. [DOI:10.1007/s12185-017-2183-7] [PMID]
14. Zhou GQ, Tang LL, Mao YP, Chen L, Li WF, Sun Y, et al. Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis. Int J Radiat Oncol Biol Phys. 2012:82(3):e359-65.
15. Gkotzamanidou M, Kastritis E, Gavriatopoulou MR, Nikitas N, Gika D, Mparmparousi D, et al. Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma. Clin Lymphoma Myeloma leuk. 2011;11(5):409-13. [DOI:10.1016/j.clml.2011.07.001] [PMID]
16. Wimazal F, Sperr WR, Kundi M, Vales A, Fonatsch C, Thalhammer-Scherrer R, et al. Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. Ann Oncol. 2008;19(5):970-6. [DOI:10.1093/annonc/mdm595] [PMID]
17. Bolwell B, Kalaycio M, Sobecks R, Andresen S, McBee M, Kuczkowski L, et al. Autologous hematopoietic cell transplantation for non-Hodgkin's lymphoma: 100 month follow-up. Bone Marrow Transplant. 2002;29(8):673-9. [DOI:10.1038/sj.bmt.1703525] [PMID]
18. Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008;14(4):418-25. [DOI:10.1016/j.bbmt.2008.01.008] [PMID] [PMCID]
19. Mohajertehran F, Ayatollahi H, Jafarian A H, Khazaeni K, Soukhtanloo M, Shakeri M, et al. Overexpression of Lactate Dehydrogenase in the Saliva and Tissues of Patients with Head and Neck Squamous Cell Carcinoma. Rep Biochem Mol Biol. 2019;7(2):142-149.
20. Sivgin S, Ozenmis T, Kaynar L, Kurnaz F, Sivgin H. Predictive Value of Pretransplant Serum Lactate Dehydrogenase (LDH) Levels for Survival in Patients who have undergone Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT). J Stem Cell Res Ther. 2012;2(118). [DOI:10.4172/2157-7633.1000118]
21. Shouval R, Teper O, Fein JA, Danylesko I, Shem Tov N, Yerushalmi R, et al. LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020;55(9):1736-1743. [DOI:10.1038/s41409-020-0829-1] [PMID]
22. Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Dis Markers. 2015;2015:635670. [DOI:10.1155/2015/635670] [PMID] [PMCID]
23. Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, et al. Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. Br J Haematol. 2017;178(6):888-895. [DOI:10.1111/bjh.14830] [PMID] [PMCID]
24. Gergis U, Kuriakose E, Shore T, Mayer S, Mark T, Pearse R, et al. Allogeneic transplantation for patients with advanced myelofibrosis: splenomegaly and high serum LDH are adverse risk factors for successful engraftment. Clin Lymphoma Myeloma Leuk. 2016;16(5):297-303. [DOI:10.1016/j.clml.2016.02.004] [PMID]
25. Manerba M, Di Ianni L, Govoni M, Roberti M, Recanatini M, Di Stefano G. Lactate dehydrogenase inhibitors can reverse inflammation induced changes in colon cancer cells. Eur J Pharm Sci. 2017;96:37-44. [DOI:10.1016/j.ejps.2016.09.014] [PMID]
26. Haas S, Hansson J, Klimmeck D, Loeffler D, Velten L, Uckelmann H, et al. Inflammation-induced emergency megakaryopoiesis driven by hematopoietic stem cell-like megakaryocyte progenitors. Cell stem cell. 2015;17(4):422-34. [DOI:10.1016/j.stem.2015.07.007] [PMID]
27. Medović R, Igrutinović Z, Radojević-Marjanović R, Marković S, Rašković Z, Simović A, et al. Clinical and laboratory differences between Epstein-Barr and cytomegalovirus infectious mononucleosis in children. Srp Arh Celok Lek. 2016;144(1-2):56-62. [DOI:10.2298/SARH1602056M] [PMID]
28. Mori T, Kato J. Cytomegalovirus infection/disease after hematopoietic stem cell transplantation. Int J Hematol. 2010;91(4):588-95. [DOI:10.1007/s12185-010-0569-x] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
